Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 3,938 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $16.46, for a total transaction of $64,819.48. Following the sale, the chief executive officer now directly owns 239,869 shares in the company, valued at $3,948,243.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) opened at $17.30 on Monday. Momenta Pharmaceuticals, Inc. has a 12-month low of $11.85 and a 12-month high of $19.25.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.12. The firm had revenue of $64.60 million during the quarter, compared to analyst estimates of $66.59 million. Momenta Pharmaceuticals had a negative net margin of 63.43% and a negative return on equity of 23.62%. Momenta Pharmaceuticals’s revenue was up 88.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 EPS. equities research analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.27 earnings per share for the current fiscal year.
A number of analysts have weighed in on MNTA shares. BidaskClub raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 9th. Stifel Nicolaus upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the stock from $18.00 to $21.00 in a research report on Thursday. Cowen set a $15.00 price target on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 1st. ValuEngine upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Finally, Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $15.33.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.